<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365369">
  <stage>Registered</stage>
  <submitdate>25/11/2013</submitdate>
  <approvaldate>11/12/2013</approvaldate>
  <actrnumber>ACTRN12613001358730</actrnumber>
  <trial_identification>
    <studytitle>The importance of microcirculation and pathophysiological role of endothelin-1 in kidney transplantation</studytitle>
    <scientifictitle>The importance of microcirculation and pathophysiological role of endothelin-1 in kidney transplantation</scientifictitle>
    <utrn>U1111-1150-7480</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Patients undergoing kidney Transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Twenty  patients undergoing kidney transplantation will be included in the study. Data regarding preoperative variables, intraoperative and postoperative variables (delayed graft function, rejection),  are prospectively collected. Patients will be followed up for 30 days
A non-invasive device (called Sidestream Dark Field imaging), that allow for clinical observation of the microcirculation will be used 30 minutes after kidney reperfusion. 
It is hand-held probe with a sterile extension for direct contact with renal parenchyma.   The tissue to be acquired in this study will be obtained from surgical specimens taken from consented participants having renal transplant.</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Correlation between microcirculation and kidney transplant outcome.
Role of endothelin-1</outcome>
      <timepoint>Post transplant outcome</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Renal function, serum marker such as creatinine, GFR, IL-18</outcome>
      <timepoint>Post operative days, 1,2,5 ,7</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients undergoing kidney transplant</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who did not agree to be included in the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Prince Alfred Transplant Institute</primarysponsorname>
    <primarysponsoraddress>missenden road, camperdown, nsw, 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Prince Alfred Transplant Institute</fundingname>
      <fundingaddress>missenden road, camperdown, nsw, 2050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Twenty patients undergoing kidney transplant will be included in the study. Data regarding preoperative variables, intraoperative and postoperative variables are prospectively collected. 
A non-invasive device (called Sidestream Dark Field imaging), that allow for clinical observation of the microcirculation will be used. 
It is hand-held probe with a sterile extension for direct contact with renal parenchyma.  
kidney biopsies are performed to assess Immunohystochemical intensity of ET-1 and other markers. The tissue to be acquired in this study will be obtained from surgical specimens taken from consented participants having kidney transplant.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital research development office</ethicname>
      <ethicaddress>missenden road, camperdown, nsw, 2050</ethicaddress>
      <ethicapprovaldate>22/11/2013</ethicapprovaldate>
      <hrec>hrec/13/rpah/89</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Carlo Pulitano</name>
      <address>Royal Prince Alfred hospital, missenden road
camperdown 2050, NSW</address>
      <phone>+61 2 951 53452</phone>
      <fax />
      <email>carlo.pulitano@gmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Carlo Pulitano</name>
      <address>Royal Prince Alfred hospital, missenden road
camperdown 2050, NSW</address>
      <phone>+61 2 951 53452</phone>
      <fax />
      <email>carlo.pulitano@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Carlo Pulitano</name>
      <address>Royal Prince Alfred hospital, missenden road
camperdown 2050, NSW</address>
      <phone>+61 2 951 53452</phone>
      <fax />
      <email>carlo.pulitano@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>